- Conditions
- Advanced Melanoma
- Interventions
- EIK1001, Pembrolizumab (KEYTRUDA® )
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Hot Springs, Arkansas • Los Angeles, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Pembrolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Morristown, New Jersey • Nashville, Tennessee + 1 more
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Atezolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- Tumor, Solid
- Interventions
- BDB018, Pembrolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas
- Conditions
- NSCLC
- Interventions
- EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Daphne, Alabama • Chandler, Arizona • Fresno, California + 33 more
- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
- Interventions
- EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 16
- States / cities
- Daphne, Alabama • Glendale, California • Orange, California + 13 more